Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating ITI-214 in Parkinson's disease assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ITI-214

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Parkinson Disease | Phase 1, Phase 2 | Status: COMPLETED